CANCER

Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial

J N Gordon, T M Trebble, R D Ellis, H D Duncan, T Johns, P M Goggin

Department of Gastroenterology, Queen Alexandra Hospital, Portsmouth, UK

Correspondence to:
Correspondence to:
Dr J N Gordon
Mailpoint 813, Level E, South Block, Southampton General Hospital, Southampton SO16 6YD, UK; j.gordon{at}soton.ac.uk

Background: Proinflammatory cytokines, especially tumour necrosis factor (TNF-), play a prominent role in the pathogenesis of cancer cachexia. Thalidomide, which is an inhibitor of TNF- synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.

Aims: To assess the safety and efficacy of thalidomide in attenuating weight loss in patients with cachexia secondary to advanced pancreatic cancer.

Methods: Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial. The primary outcome was change in weight and nutritional status.

Results: Thirty three patients (16 control, 17 thalidomide) were evaluated at four weeks, and 20 patients (eight control, 12 thalidomide) at eight weeks. At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm³ in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference –2.59 kg (95% confidence interval (CI) –4.3 to –0.8); p = 0.005) and 4.46 cm³ (absolute difference –5.6 cm³ (95% CI –8.9 to –2.2); p = 0.002) in the placebo group. At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm³ in AMA compared with a loss of 3.62 kg (absolute difference –3.57 kg (95% CI –6.8 to –0.3); p = 0.034) and 8.4 cm³ (absolute difference –7.9 cm³ (95% CI –14.0 to –1.8); p = 0.014) in the placebo group. Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).

Conclusion: Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.

Abbreviations: TNF, tumour necrosis factor; IL, interleukin; IFN, interferon; PIF, proteolysis inducing factor; NFB, nuclear factor B; IB, inhibitor B; MAC, mid upper arm circumference; TSF, triceps skinfold thickness; AMA, arm muscle area; EPA, eicosapentaenoic acid; EORTC QLQ, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire

Keywords: thalidomide; cachexia; pancreatic cancer; weight loss; randomised controlled trial

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Thalidomide and cancer cachexia: old problem, new hope?

M Stroud
Gut 2005 54: 447-448. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Lee, S. M., Rudd, R., Woll, P. J., Ottensmeier, C., Gilligan, D., Price, A., Spiro, S., Gower, N., Jitlal, M., Hackshaw, A. (2009). Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. JCO 27: 5248-5254 [Abstract] [Full Text]  
• Lee, S. M., Woll, P. J., Rudd, R., Ferry, D., O'Brien, M., Middleton, G., Spiro, S., James, L., Ali, K., Jitlal, M., Hackshaw, A. (2009). Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. JNCI J Natl Cancer Inst 101: 1049-1057 [Abstract] [Full Text]  
• Tisdale, M. J. (2009). Mechanisms of Cancer Cachexia. Physiol. Rev. 89: 381-410 [Abstract] [Full Text]  
• Radbruch, L., Strasser, F., Elsner, F., Goncalves, J. F., Loge, J., Kaasa, S., Nauck, F., Stone, P., the Research Steering Committee of the European As, (2008). Fatigue in palliative care patients -- an EAPC approach. Palliat Med 22: 13-32 [Abstract]  
• Doyle, C., Kushi, L. H., Byers, T., Courneya, K. S., Demark-Wahnefried, W., Grant, B., McTiernan, A., Rock, C. L., Thompson, C., Gansler, T., Andrews, K. S., for the 2006 Nutrition, Physical Activity and Canc, (2006). Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices. CA Cancer J Clin 56: 323-353 [Abstract] [Full Text]  
• Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.-D., Schnelle, M., Reif, M., Cerny, T. (2006). Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group. JCO 24: 3394-3400 [Abstract] [Full Text]  
• Gordon, J.N., Green, S.R., Goggin, P.M. (2005). Cancer cachexia. QJM 98: 779-788 [Abstract] [Full Text]  
• Stroud, M (2005). Thalidomide and cancer cachexia: old problem, new hope?. Gut 54: 447-448 [Full Text]